25. Scheinberg M, Machado L, M Castro L, Ferreira S, Michalany N. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun. 2021;4:100099. doi:10.1016/j. jtauto.2021.100099
26. Kochar B, Herfarth N, Mamie C, Navarini A, Scharl M, Herfarth H. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17(5):991-993. doi:10.1016/j.cgh.2018.10.047
27. Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540-2546. doi:10.1056/NEJMoa1805958
28. Talty R, Damsky W, King B. Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis. JAAD Case Rep. 2021;16:62-64. doi:10.1016/j. jdcr.2021.08.012
29. Wei J, Kallenbach L, Kreider M, Leung T, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360-361. doi:10.1016/j. jdcr.2019.02.006
30. Fetter T, Smith P, Guel T, Braegelmann C, Bieber T, Wenzel J. Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. 2020;11:344. doi:10.3389/ fimmu.2020.00344
31. Wallace D, Furie R, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-231. doi:10.1016/S0140-6736(18)31363- 1
32. Bonnardeaux E, Dutz J. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2021;20:61-64. doi:10.1016/j.jdcr.2021.09.030
33. McGaugh S, Kallis P, De Benedetto A, Thomas R. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review. Dermatol Ther. 2022;35(6):e15437. doi:10.1111/dth.15437
34. Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12:790125. doi:10.3389/fimmu.2021.790125
35. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). U.S. Food and Drug Administration. February 4, 2021. Accessed August 2022. https://www.fda.gov/drugs/drug-safetyand- availability/initial-safety-trial-results-find-increased-risk-serious-heartrelated- problems-and-cancer-arthritis
36. Li Y, Huo J, Cao Y, et al. Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation. Ann Rheum Dis. 2020;79(9):1255-1257. doi:10.1136/ annrheumdis-2020-217250
37. Wang C, Wong T, Hsu W. Extended-release tofacitinib for refractory Behçet disease. Medicine (Baltimore). 2022;101(15):e29189. doi: 10.1097/ MD.0000000000029189.
38. King B, Lee A, Choi J. Treatment of hypereosinophilic syndrome with cutaneous involvement with the jak inhibitors tofacitinib and ruxolitinib. J Invest Dermatol. 2017;137(4):951-954. doi:10.1016/j.jid.2016.10.044
39. Liew S, Nichols K, Klamerus K, Li J, Zhang M, Foulks G. Tofacitinib (CP- 690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology. 2012;119(7):1328-1335. doi:10.1016/j. ophtha.2012.01.028
40. Fukunaga A, Ito M, Nishigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol. 2018;98(9):904-905. doi:10.2340/00015555-3006
41. Bloomfield M, Kanderová V, ParaÄková Z, et al. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel stat1 gainof- function mutation. J Clin Immunol. 2018;38(5):589-601. doi:10.1007/ s10875-018-0519-6
42. Chen C, Chiu C, Bai L. Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib. Eur J Cancer. 2019;113:69-71. doi:10.1016/j. ejca.2019.03.016
26. Kochar B, Herfarth N, Mamie C, Navarini A, Scharl M, Herfarth H. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17(5):991-993. doi:10.1016/j.cgh.2018.10.047
27. Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540-2546. doi:10.1056/NEJMoa1805958
28. Talty R, Damsky W, King B. Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis. JAAD Case Rep. 2021;16:62-64. doi:10.1016/j. jdcr.2021.08.012
29. Wei J, Kallenbach L, Kreider M, Leung T, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360-361. doi:10.1016/j. jdcr.2019.02.006
30. Fetter T, Smith P, Guel T, Braegelmann C, Bieber T, Wenzel J. Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. 2020;11:344. doi:10.3389/ fimmu.2020.00344
31. Wallace D, Furie R, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-231. doi:10.1016/S0140-6736(18)31363- 1
32. Bonnardeaux E, Dutz J. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2021;20:61-64. doi:10.1016/j.jdcr.2021.09.030
33. McGaugh S, Kallis P, De Benedetto A, Thomas R. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review. Dermatol Ther. 2022;35(6):e15437. doi:10.1111/dth.15437
34. Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12:790125. doi:10.3389/fimmu.2021.790125
35. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). U.S. Food and Drug Administration. February 4, 2021. Accessed August 2022. https://www.fda.gov/drugs/drug-safetyand- availability/initial-safety-trial-results-find-increased-risk-serious-heartrelated- problems-and-cancer-arthritis
36. Li Y, Huo J, Cao Y, et al. Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation. Ann Rheum Dis. 2020;79(9):1255-1257. doi:10.1136/ annrheumdis-2020-217250
37. Wang C, Wong T, Hsu W. Extended-release tofacitinib for refractory Behçet disease. Medicine (Baltimore). 2022;101(15):e29189. doi: 10.1097/ MD.0000000000029189.
38. King B, Lee A, Choi J. Treatment of hypereosinophilic syndrome with cutaneous involvement with the jak inhibitors tofacitinib and ruxolitinib. J Invest Dermatol. 2017;137(4):951-954. doi:10.1016/j.jid.2016.10.044
39. Liew S, Nichols K, Klamerus K, Li J, Zhang M, Foulks G. Tofacitinib (CP- 690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology. 2012;119(7):1328-1335. doi:10.1016/j. ophtha.2012.01.028
40. Fukunaga A, Ito M, Nishigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol. 2018;98(9):904-905. doi:10.2340/00015555-3006
41. Bloomfield M, Kanderová V, ParaÄková Z, et al. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel stat1 gainof- function mutation. J Clin Immunol. 2018;38(5):589-601. doi:10.1007/ s10875-018-0519-6
42. Chen C, Chiu C, Bai L. Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib. Eur J Cancer. 2019;113:69-71. doi:10.1016/j. ejca.2019.03.016
AUTHOR CORRESPONDENCE
Adam Friedman MD FAAD ajfriedman@mfa.gwu.edu
